Seattle-based vaccine developer Immune Design’s new CEO is Carlos Paya, the former president of Ireland-based biotech Elan. Paya is replacing Immune Design’s founding CEO, Steve Reed, who will continue to serve on the company’s executive management team and board, according to Xconomy Seattle.

At Elan, Paya oversaw commercial, marketing, R&D, and clinical operations since 2008. Before that, he was employed by Eli Lilly as vice president of Lilly Research Laboratories.